You are here

Plerixafor in Diabetic Wound Healing

A new STEM CELLS Translational Medicine article from the lab of Gian Paolo Fadini (University of Padova, Padova, Italy) report on their results of a phase IIa clinical trial evaluating the CXCR4 antagonist plerixafor as a means to mobilize hematopoietic stem/progenitor cells and improve ischemic diabetic wound healing. Unexpectedly, Bonora et al. now report that the mobilization of diabetic stem cells by plerixafor treatment exerts an adverse effect on tissue repair, with a larger wound size observed when compared to a placebo control.